奥沙利铂联合化疗治疗76例晚期胃癌的近期疗效观察  

Clinical Results of Regimen Based on Oxaliplatin in Chemotherapy for 76 Patients With Advanced Gastric Cancer

作　　者：李云霞[1] 刘新兰[1] 王宁菊[1] 

机构地区：[1]宁夏医学院附属医院肿瘤内科,750004

出　　处：《实用癌症杂志》2006年第4期381-383,398,共4页The Practical Journal of Cancer

摘　　要：目的 观察国产奥沙利铂（L-OHP）联合亚叶酸钙（LV）和5-氟脲嘧啶（5-Fu）治疗晚期胃癌的疗效和毒副反应,并与传统方案进行比较.方法 采用非随机分组方法将76例晚期胃癌患者分为治疗组（A组）40例和对照组（B组）36例.A组：L-OHP 130 mg/m^2,静脉滴注3～4 h,d1;LV 200 mg/m^2,静脉滴注2h,d1～5;5-Fu 400 mg/m^2,静脉滴注6 h,d1～5 .B组：DDP 15 mg/m^2,静脉滴注,d1～5;VP-16 75 mg/m^2,静脉滴注2 h,d1～3;LV与5-Fu用法同A组.21天重复1次,2个周期后评价疗效.结果 A组有效率为55.0% （22/40）,B组有效率为33.3% （12/36）,有显著性差异（P＜0.05）;A组中位生存时间10.0个月,1年生存率为42.5%（17/40）,B组中位生存时间8.5个月,1年生存率为36.1%（13/36）（P＞0.05）.有效患者中位缓解时间：A组为7.5个月,B组为5.3个月,有显著性差异（P＜0.05）.A组主要不良反应为外周神经毒性,其发生率为60.0%（24/40）,较B组30.5%（11/36）为高（P＜0.01）,恶心呕吐及白细胞下降的发生率分别为45.0%（18/40）、57.5%（23/40）,较B组的发生率83.3%（30/36）、80.5%（29/36）明显为低（P＜0.01）.结论 L-OHP联合LV和5-Fu方案治疗晚期胃癌临床疗效较好,不良反应可以耐受,而且安全.Objective To evaluate the response and toxicity of Oxaliplatin（L-OHP） combined with leucovorin （LV） and 5- fluorouracil（5-Fu） regimen for patients with advanced gastric cancer,and compare with traditional chemotherapy regimen. Methods Seventy-six patients with advanced gastric cancer were divided into treatment group （group A） forty patients and control group （group B）thirty-six patients using non-randomized method. The regimen of the group A was L-OHP 130 mg/m^2, iv infusion for 3-- 4 hours on day 1; LV 200 mg/m^2,iv infusion for 2 hours followed by 5-Fu 400 mg/m^2,iv infusion for 6 hours from day 1 to 5.The regimen of the group B was DDP 15 mg/m^2,iv infusion from day 1 to 5;VP-16 75 mg/m^2,iv infusion from day 1 to 3; the usage of LV and 5-Fu were similar to the group A. All patients were evaluated after 2 cycles （every cycle lasted 21 days）. Results The response rate was 55.0%（22/40） in group A and 33.33% （12/36） in group B. The statistic difference was seen in two groups（P〈0.05）.The median survival time and 1-year survival rate were 10 months and 42.5% （17/40） for group A versus 8.5 months and 36.1% （13/36）for group B. There were no statistic difference in two groups （P 〉 0.05）. The median time to progression was 7.5 months in group A and 5.3 months in group B（P〈0.05）.The main toxicities were neuro-sensory toxicity in group A and vomiting and leucopenia in group B. There were significant statistically difference in twogroups （P 〈： 0.01 ）. Conclusion Oxaliplatin combined with LV/5-Fu regimen is high response and well tolerable for advanced gastric cancer,which can be practiced ,safely.

关 键 词：胃癌 奥沙利铂 联合化疗 

分 类 号：R730.53[医药卫生—肿瘤] R735.2[医药卫生—临床医学]